Holen Sie sich die Stockscreener-App
13.47
2.11%
-0.29
Schlusskurs vom Vortag:
$13.76
Offen:
$13.78
24-Stunden-Volumen:
980.98K
Relative Volume:
0.95
Marktkapitalisierung:
$856.66M
Einnahmen:
Nettoeinkommen (Verlust:
$-129.61M
KGV:
-4.5094
EPS:
-2.9871
Netto-Cashflow:
$-116.59M
1W Leistung:
-6.39%
1M Leistung:
-19.10%
6M Leistung:
-38.44%
1J Leistung:
+37.66%
1-Tages-Spanne:
$13.03
$14.10
1-Wochen-Bereich:
$12.85
$14.45
52-Wochen-Spanne:
$8.36
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Firmenname
Jade Biosciences Inc
Sektor
Branche
Telefon
(781) 312-3013
Adresse
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
13.47 | 856.66M | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-15 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Eingeleitet | BTIG Research | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-05-07 | Eingeleitet | Wedbush | Outperform |
| 2025-05-05 | Eingeleitet | Stifel | Buy |
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in DermatomyositisSlideshow - Seeking Alpha
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Yahoo Finance
Yarrow Bioscience Announces Proposed Underwritten Public Offering - Yahoo Finance
JBIO: JADE101 leads a robust pipeline with best-in-class data and rapid path to market in IgA nephropathy - TradingView
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com India
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com Canada
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com UK
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com South Africa
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com Nigeria
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 - Investing.com
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com Canada
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com UK
Jade Biosciences Company Profile & Introduction - moomoo.com
Jade Biosciences Company Profile & Introduction - Moomoo
JADE BIOSCIENCES, INC. : CLEAR STREET RAISES TARGET PRICE TO $48 FROM $25 - moomoo.com
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
LifeSci Capital Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade (JBIO) Financial Update: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Investor Response: Shares End With Little Net Change at the CloseEarnings Quality Analysis - vinanet.vn
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection - Yahoo Finance
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpWhat's Next? - MarketBeat
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027 - Pluang
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences Company Profile & Introduction - Moomoo
Jade Biosciences Company Profile & Introduction - moomoo.com
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights - Benzinga España
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Jade Biosciences (JBIO) Advances 2.4% to $22.89 as Buyers Defend Key Support ZoneFlat Correction - vinanet.vn
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $47 - Moomoo
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jade Biosciences Is Maintained at Buy by BTIG - Moomoo
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com India
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Canada
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com UK
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Finanzdaten der Jade Biosciences Inc-Aktie (JBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):